Quantcast

Latest medullary thyroid cancer Stories

2011-12-20 22:42:34

Procedure may reduce recurrence rates, lower tumor marker levels Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women. A new study indicates that routinely removing lymph nodes in the neck in these cancer patients may help prevent the disease from coming back. When thyroid cancer metastasizes, lymph nodes in the neck may be affected, but these lymph-node tumors can be tiny and may not be detected by ultrasounds done before surgery...

2011-06-06 14:59:19

A mutant gene long thought to accelerate tumor growth in thyroid cancer patients actually inhibits the spread of malignant cells, showing promise for novel cancer therapies, a Mayo Clinic study has found. The findings will be presented by Mayo Clinic researcher Honey Reddi, Ph.D., at the Endocrine Society meeting in Boston. Dr. Reddi's discovery could have widespread implications in cancer research and endocrinology. It could help oncologists sharpen the diagnosis of specific types of thyroid...

2011-04-06 15:24:00

Vandetanib is first drug approved for medullary thyroid cancer SILVER SPRING, Md., April 6, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Thyroid cancer is a cancerous growth of the thyroid gland, which is...

2011-02-01 23:40:25

Positron emission tomography (PET) can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine. Currently being tested in clinical trials, vandetanib inhibits the function of the RET (rearranged-during-transfection protein) proto-oncogene and other protein kinases involved in the...

2010-12-28 08:21:30

(Ivanhoe Newswire) "“ Variations of a gene are associated with a type of tumor that forms within the adrenal gland, and were found in an age group uncommon for these types of tumors. Pheochromocytomas and paragangliomas are types of tumors. Pheochromocytomas form in the adrenal gland causing it to make too much adrenaline. Pheochromocytomas can cause high blood pressure, pounding headaches, heart palpitations, flushing of the face, nausea, and vomiting. Paragangliomas are rare, usually...

2010-12-02 14:16:00

WILMINGTON, Del., Dec. 2, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC). (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) The Advisory...

2010-09-23 01:00:00

LONDON, Sept. 23 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011. (Logo:...

2010-06-07 08:14:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The results of the ZETA study were presented today at the American Society of Clinical Oncology...

2010-05-18 12:28:01

Individuals with papillary thyroid cancer that has not spread beyond the thyroid gland appear to have favorable outcomes regardless of whether they receive treatment within the first year after diagnosis, according to a report in the May issue of Archives of Otolaryngology"“Head & Neck Surgery, one of the JAMA/Archives journals. Papillary thyroid cancer is commonly found on autopsy among individuals who died of other causes, according to background information in the article....


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related